Confronting the Digital Dilemma in Healthcare’s Quest for Innovation
MedCity News
by Mika Newton
2h ago
The imperative to modernize healthcare communication methods extends beyond mere technological upgrades. Rather, it’s a fundamental necessity to enhance patient care, streamline healthcare delivery, and unlock the full potential of medical innovation. The post Confronting the Digital Dilemma in Healthcare’s Quest for Innovation appeared first on MedCity News ..read more
Visit website
Medicare’s Push To Improve Chronic Care Attracts Businesses, but Not Many Doctors
MedCity News
by Arundhati Parmar
11h ago
Medicare’s Chronic Care Management program reduced emergency room and in-patient hospital visits and lowered total health spending, but uptake has been sluggish for a variety of reasons. The post Medicare’s Push To Improve Chronic Care Attracts Businesses, but Not Many Doctors appeared first on MedCity News ..read more
Visit website
23andMe: What If …
MedCity News
by Arundhati Parmar
11h ago
A much diminished 23andMe exists today, a far cry from the phenomenon that it was in the world consumer DNA testing. Could things have unfolded differently under a different leader with a different vision? The post 23andMe: What If … appeared first on MedCity News ..read more
Visit website
Healthcare Docket: Help Wanted — Doctor Expert Witnesses
MedCity News
by Ron Harman King
11h ago
Major malpractice verdicts have spiked in recent years.  The post Healthcare Docket: Help Wanted — Doctor Expert Witnesses appeared first on MedCity News ..read more
Visit website
Novel Parkinson’s Disease Drug Will Join AbbVie With Positive Phase 3 Data In Hand
MedCity News
by Frank Vinluan
17h ago
Cerevel Therapeutics drug tavapadon met the main and secondary goals of a pivotal Parkinson’s disease clinical trial. That drug and others will join the neuroscience portfolio of AbbVie, which is in the process of acquiring Cerevel. The post Novel Parkinson’s Disease Drug Will Join AbbVie With Positive Phase 3 Data In Hand appeared first on MedCity News ..read more
Visit website
Hospital M&A Activity in 2024: What to Expect
MedCity News
by Katie Adams
17h ago
Q1 2024 saw a significant rise in the number of hospital M&A deals compared to the past three Q1s. Experts believe this M&A activity will continue to climb throughout this year and next — motivated by both financial distress and hospitals’ desire to improve strategic business lines like value-based care and digital healthcare services. The post Hospital M&A Activity in 2024: What to Expect appeared first on MedCity News ..read more
Visit website
In the World of Interoperability, How to Meaningfully Strengthen Cybersecurity
MedCity News
by Ryan Hamilton
23h ago
Achieving strong cybersecurity is a vast, interconnected web that must incorporate the correct software, procedures, and workflows and take into account the human element across an entire organization. The post In the World of Interoperability, How to Meaningfully Strengthen Cybersecurity appeared first on MedCity News ..read more
Visit website
FDA Announces Recall of Heart Pumps Linked to Deaths and Injuries
MedCity News
by Arundhati Parmar
1d ago
The recall comes years after surgeons say they first noticed problems with the HeartMate II and HeartMate 3, manufactured by Thoratec Corp., a subsidiary of Abbott Laboratories. The devices are not currently being removed from the market. The post FDA Announces Recall of Heart Pumps Linked to Deaths and Injuries appeared first on MedCity News ..read more
Visit website
What Does the FTC’s $7M Fine Against Cerebral Mean for the Industry?
MedCity News
by Katie Adams
1d ago
This week, the FTC ordered Cerebral to pay a $7 million fine, accusing the company of mishandling users’ sensitive health data and misleading consumers about cancellation policies. Experts agree that other virtual healthcare providers need to work on their legal and compliance strategies in order to avoid a similar fate. The post What Does the FTC’s $7M Fine Against Cerebral Mean for the Industry? appeared first on MedCity News ..read more
Visit website
Eli Lilly Shows Obesity Drug Zepbound Can Treat Sleep Apnea Too
MedCity News
by Frank Vinluan
2d ago
Eli Lilly drug tirzepatide, marketed as Zepbound for weight management, has results from two Phase 3 studies showing reductions in the breathing problems caused by obstructive sleep apnea. Lilly is now preparing regulatory submissions to add this indication to the drug’s label. The post Eli Lilly Shows Obesity Drug Zepbound Can Treat Sleep Apnea Too appeared first on MedCity News ..read more
Visit website

Follow MedCity News on FeedSpot

Continue with Google
Continue with Apple
OR